Stockscreener 앱 받기
31.45
0.66%
-0.21
시간 외 거래:
31.50
0.05
+0.16%
전일 마감가:
$31.66
열려 있는:
$31.81
하루 거래량:
1.57M
Relative Volume:
0.75
시가총액:
$3.03B
수익:
$522.75M
순이익/손실:
$-558.99M
주가수익비율:
-4.8609
EPS:
-6.47
순현금흐름:
$-439.53M
1주 성능:
+0.77%
1개월 성능:
+0.51%
6개월 성능:
-5.16%
1년 성능:
-41.62%
1일 변동 폭
$30.93
$31.84
1주일 범위
$29.57
$32.10
52주 변동 폭
$25.81
$57.99
울트라제닉스 파마슈티컬 Stock (RARE) Company Profile
명칭
Ultragenyx Pharmaceutical Inc
전화
415-483-8800
주소
60 LEVERONI COURT, NOVATO, CA
RARE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
31.45 | 3.05B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | William Blair | Outperform |
| 2024-06-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-04-22 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-06-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-12-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-03 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-08-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-03-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 개시 | H.C. Wainwright | Buy |
| 2021-08-19 | 개시 | UBS | Sell |
| 2021-07-15 | 개시 | Guggenheim | Neutral |
| 2021-06-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-05-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-05-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-02 | 재개 | Stifel | Buy |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-11-24 | 재개 | Evercore ISI | In-line |
| 2020-11-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2019-08-02 | 재개 | Wedbush | Outperform |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 개시 | Goldman | Neutral |
| 2018-04-18 | 업그레이드 | SunTrust | Hold → Buy |
| 2018-03-22 | 재개 | Piper Jaffray | Overweight |
| 2018-02-21 | 재확인 | Stifel | Buy |
| 2018-01-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 개시 | Credit Suisse | Outperform |
| 2017-12-05 | 재확인 | Barclays | Equal Weight |
| 2017-12-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-09-14 | 업그레이드 | Wedbush | Neutral → Outperform |
모두보기
울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스
Can Ultragenyx Pharmaceutical Inc. (UP0) stock hold up in economic slowdownJuly 2025 WrapUp & AI Forecast for Swing Trade Picks - newser.com
Ultragenyx Pharmaceutical Inc. stock prediction for this weekWeekly Trade Review & Reliable Trade Execution Plans - newser.com
What sentiment indicators say about Ultragenyx Pharmaceutical Inc. stockCPI Data & Capital Protection Trade Alerts - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE) - MarketBeat
What moving averages say about Ultragenyx Pharmaceutical Inc.2025 Technical Overview & Free Weekly Watchlist of Top Performers - newser.com
Does Ultragenyx Pharmaceutical Inc. show high probability of reboundWeekly Risk Report & Advanced Swing Trade Entry Plans - newser.com
Predicting Ultragenyx Pharmaceutical Inc. trend using moving averagesJuly 2025 Chart Watch & Safe Entry Point Identification - newser.com
What drives Ultragenyx Pharmaceutical Inc stock priceTechnical Analysis Insights & Hidden Gems with Outstanding Profit Margins - earlytimes.in
Wealth Enhancement Advisory Services LLC Takes $353,000 Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE) - Yahoo Finance
Pattern recognition hints at Ultragenyx Pharmaceutical Inc. upsideWeekly Volume Report & High Conviction Buy Zone Picks - newser.com
Why Ultragenyx Pharmaceutical Inc. (UP0) stock signals breakout potentialJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - newser.com
How to read the order book for Ultragenyx Pharmaceutical Inc.Share Buyback & Free Daily Entry Point Trade Alerts - newser.com
Ultragenyx Pharmaceutical Inc. stock trend outlook and recovery path2025 Key Lessons & Weekly High Potential Stock Alerts - newser.com
Will Ultragenyx Pharmaceutical Inc. (UP0) stock outperform energy sector in 2025Watch List & High Accuracy Swing Entry Alerts - newser.com
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $80 - 富途牛牛
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
62,232 Options & 34,564 RSUs: Ultragenyx Grants Inducement Award to New Hire, Grant Date Sep 30, 2025 - Stock Titan
Ultragenyx Pharmaceutical (RARE): Valuation Perspectives Following Regulatory Milestones and Pipeline Progress - Yahoo Finance
Ultragenyx Pharmaceutical (RARE): Evaluating Valuation After Strategic Leadership Transition with Eric Olson - Sahm
Using RSI to spot recovery in Ultragenyx Pharmaceutical Inc.Weekly Investment Recap & Smart Money Movement Tracker - newser.com
Tools to monitor Ultragenyx Pharmaceutical Inc. recovery probabilityAnalyst Downgrade & Precise Swing Trade Entry Alerts - newser.com
How to monitor Ultragenyx Pharmaceutical Inc. with trend dashboards2025 Short Interest & High Return Trade Guides - newser.com
How Might Ultragenyx (RARE) Leverage Dealmaking Expertise to Shape Its Long-Term Growth Strategy? - Yahoo Finance
Ultragenyx (RARE) Poised for Positive Developments, Says JPMorga - GuruFocus
Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline - Insider Monkey
Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical - openPR.com
Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical Progress by 8+ Global Leaders – DelveInsight | Featuring Ultragenyx Pharmaceutical Inc, JCR Pharmaceuticals Co., Ltd., GC Biopharma Corp, D - The Globe and Mail
Ultragenyx Pharmaceutical Hits Day High with Strong 8.12% Intraday Surge - Markets Mojo
Ultragenyx Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
United States Osteogenesis Imperfecta Treatment Market - openPR.com
Ultragenyx appoints Eric Olson as chief business officer By Investing.com - Investing.com Nigeria
Revolution Medicines hires Mirati, ALX vet Sandler - biocentury.com
7 Most Promising Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Ultragenyx appoints Eric Olson as chief business officer and executive vice president - MarketScreener
Ultragenyx appoints Eric Olson as chief business officer - Investing.com India
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President - GlobeNewswire
Ultragenyx appoints Eric Olson Chief Business Officer - TipRanks
Ultragenyx Pharmaceutical Inc. Appoints Eric Olson as Chief Business Officer Following Retirement of Thomas Kassberg - Quiver Quantitative
$15B+ Deal Veteran Eric Olson Joins Rare Disease Leader Ultragenyx as Chief Business Officer - Stock Titan
울트라제닉스 파마슈티컬 (RARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.74%
자본화:
|
볼륨(24시간):